Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob George

Showing results (771-780 of 849) with videos related to

Pageof 85
Sort By:
Metabolism: Clinical and Experimental|December 27, 2021
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLDLiang-Jie Tang, Hong-Lei Ma, Mohammed Eslam, et al.
Cell Death & Disease|July 27, 2025
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinomaTasnuva D Kabir, Samuel Beck, Lisa M Stuart, et al.
Hepatology International|October 2, 2020
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver diseaseMohammed Eslam, Shiv K Sarin, Vincent Wai-Sun Wong, et al.
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for previously untreated chronic hepatitis C virus infectionIra M Jacobson, John G McHutchison, Geoffrey Dusheiko, et al.
Antiviral Therapy|April 20, 2017
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL studyJohn Lubel, Simone Strasser, Katherine A Stuart, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 27, 2018
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver DiseaseZobair M Younossi, Maria Stepanova, Janus Ong, et al.
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Journal of Hepatology|December 13, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?Jeffrey V Lazarus, Henry E Mark, Marcela Villota-Rivas, et al.
Pageof 85

Showing results (771-780 of 849) with videos related to

Sort By:
Pageof 85
Metabolism: Clinical and Experimental|December 27, 2021
Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLDLiang-Jie Tang, Hong-Lei Ma, Mohammed Eslam, et al.
Cell Death & Disease|July 27, 2025
Inhibition of the Caveolin-1 pathway promotes apoptosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinomaTasnuva D Kabir, Samuel Beck, Lisa M Stuart, et al.
Hepatology International|October 2, 2020
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver diseaseMohammed Eslam, Shiv K Sarin, Vincent Wai-Sun Wong, et al.
Journal of Gastroenterology and Hepatology|July 8, 2026
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient-Reported OutcomesGeorge Papatheodoridis, Maria Buti, Yusuf Yilmaz, et al.
The New England Journal of Medicine|June 24, 2011
Telaprevir for previously untreated chronic hepatitis C virus infectionIra M Jacobson, John G McHutchison, Geoffrey Dusheiko, et al.
Antiviral Therapy|April 20, 2017
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL studyJohn Lubel, Simone Strasser, Katherine A Stuart, et al.
Journal of Gastroenterology and Hepatology|October 13, 2018
Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL studyLai Wei, Ji Dong Jia, Fu Sheng Wang, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 27, 2018
Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver DiseaseZobair M Younossi, Maria Stepanova, Janus Ong, et al.
Nature Genetics|April 11, 2017
IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosisMohammed Eslam, Duncan McLeod, Kebitsaone Simon Kelaeng, et al.
Journal of Hepatology|December 13, 2021
The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?Jeffrey V Lazarus, Henry E Mark, Marcela Villota-Rivas, et al.
Pageof 85